Xarelto Lawsuit Update: Number of Cases Filed in Phila. Mass Tort Group Rising

November 02, 2015 – – BloodThinnerHelp.com reports today with an update on the Xarelto Philadelphia mass tort litigation. There are currently 461 cases filed in the mass tort group against Xarelto’s manufacturers and the number has been steadily rising over the past few weeks. For more detailed information about the Xarelto lawsuits, click here.

Xarelto Lawsuit Allegations:

These cases are able to be consolidated into a mass tort litigation because they all make similar allegations against the same defendants, the manufacturers of Xarelto Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson.

These lawsuits are alleging that Xarelto causes serious, uncontrollable internal bleeding, that the manufacturers of Xarelto failed to adequately warn doctors and patients about the true dangers of Xarelto, and that the manufacturers of Xarelto were negligent in releasing the drug to market without a corresponding antidote. The lawsuits are alleging that Xarelto’s lack of antidote makes the drug particularly dangerous. A full list of cases filed in the mass tort group can be found here.

The Real Dangers of Xarelto:

The lawsuits are alleging that Xarelto is much more dangerous than other blood thinners on the market because Xarelto does not have a corresponding antidote that will reverse the drug’s effects. The most commonly prescribed traditional blood thinner, Warfarin, has an antidote of Vitamin K, so if a patient taking Warfarin suffers an internal bleeding injury, vitamin K can be administered and the blood will be able to clot again. No such antidote exists for Xarelto. If a Xarelto user suffers an internal bleed, there is no antidote to make the blood clot again.

Critics of Xarelto state that the internal bleeding risk of Xarelto could potentially be minimized if patients were required to have their blood monitored as they are on Warfarin. These critics also claim that there is no benefit to take Xarelto over Warfarin, especially considering the lack of antidote. There are currently two ‘Black Box’ warnings attached to Xarelto by the FDA. The black box warning is the most strict warning the FDA can issue to a drug short of recalling it.

For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

ReleaseID: 60005049